Evidence map›Paper›PMID 12843245›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2003

Antibody cross-linking of myelin oligodendrocyte glycoprotein leads to its rapid repartitioning into detergent-insoluble fractions, and altered protein phosphorylation and cell morphology.

C B Marta, C M Taylor, T Coetzee, T Kim, S Winkler, R Bansal, S E Pfeiffer

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 72 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Oligodendroglial membrane dynamics in relation to myelin biogenesis.Cellular and molecular life sciences : CMLS · 2016
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. In vivo composition of NMDA receptor signaling complexes differs between membrane subdomains and is modulated by PSD-95 and PSD-93.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2010
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

C B MartaDepartment of Neuroscience, University of Connecticut Medical School, Farmington, Connecticut 06030-3401, USA. Marta@up.uchc.edu
C M Taylor
T Coetzee
T Kim
S Winkler
R Bansal
S E Pfeiffer
University of Connecticut · US

Funding

PROTEOMIC MAPPING OF MYELIN AND ITS MEMBRANE SUBDOMAINSR01NS041078 · NINDS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI BANSAL, RASHMI · 2000 to 2009
$3.3M
Oligodendrocyte Differentiation and Myelin BiogenesisR01NS010861 · NINDS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI BANSAL, RASHMI · 1985 to 2007
$2.3M
GUKHOLDER AT THE NEUROMUSCULAR JUNCTIONF31NS010861 · NINDS · UNIVERSITY OF MASSACHUSETTS AMHERST · PI GRAMATES, SIAN L · 1999 to 2000
$5k
NINDS NIH HHS F31 NS010861NINDS NIH HHS NS10861NINDS NIH HHS NS41078NINDS NIH HHS R01 NS010861NINDS NIH HHS R01 NS041078
6 · The paper itself

Abstract

Myelin oligodendrocyte glycoprotein (MOG) is, quantitatively, a relatively minor component of the myelin membrane. Nevertheless, peritoneal administration of MOG evokes potent cellular and humoral immunoreactivity, resulting in an experimental allergic encephalitis with immunopathology similar to multiple sclerosis. Moreover, antibodies against MOG cause myelin destruction in situ. Therefore, it appears that MOG-related demyelination is dependent on anti-MOG antibody, but the mechanism(s) by which it occurs is unclear. Of potential significance are observations that some proteins are selectively partitioned into specialized plasma membrane microdomains rich in glycosphingolipids and cholesterol ("lipid rafts"). In particular, during ligand or antibody cross-linking, various plasma membrane receptors undergo enhanced partitioning into rafts as an obligatory first step toward participation in early signal transduction events. In contrast to mature myelin, in oligodendrocytes (OLs) in culture MOG is not raft associated [Triton X-100 (TX-100) soluble, 4 degrees C]. However, in this study we show that antibody cross-linking (anti-MOG plus secondary antibody) of MOG on the surface of OLs results in the repartitioning of approximately 95% of MOG into the TX-100-insoluble fraction. This repartitioning of MOG is rapid (<or=1 min), antibody dose dependent, requires an intact cytoskeleton, leads to phosphorylation or dephosphorylation of tyrosine, serine, and threonine residues in specific proteins (e.g., beta-tubulin, Gbeta1-2), and invokes a rapid retraction of OL processes. After removal of the cross-linking antibodies, these events are reversed. We hypothesize that antibody-mediated repartitioning of MOG into TX-100-insoluble glycosphingolipid-cholesterol-rich microdomains initiates specific cellular signaling that could be related to initial steps of MOG-mediated demyelination.

Indexed as

AntibodiesCell DifferentiationCells, CulturedCross-Linking ReagentsCytoskeletonDemyelinating DiseasesDetergentsDose-Response Relationship, DrugEnzyme InhibitorsMembrane MicrodomainsMyelin-Associated GlycoproteinMyelin-Oligodendrocyte GlycoproteinMyelin ProteinsOctoxynolOligodendrogliaPhosphorylationAntibodiesCross-Linking ReagentsDetergentsEnzyme InhibitorsMyelin-Associated GlycoproteinMyelin-Oligodendrocyte GlycoproteinMyelin ProteinsOctoxynolTubulin

Identifiers

PMID12843245
PMCPMC6741276
OpenAlexW1480342093

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.